<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862600</url>
  </required_header>
  <id_info>
    <org_study_id>HML-PHX-005</org_study_id>
    <nct_id>NCT02862600</nct_id>
  </id_info>
  <brief_title>Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure</brief_title>
  <official_title>A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Metabolics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart Metabolics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of perhexiline on exercise performance
      (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe
      heart failure following dosing for 16 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of VO2MAX</measure>
    <time_frame>end of Period 2 (Week 16)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of VO2MAX</measure>
    <time_frame>end of Period 1 (Week 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of VO2MAX</measure>
    <time_frame>end of Period 1 (Week 8) compared to end of Period 2 (Week 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the six-minute walk test</measure>
    <time_frame>end of Period 1 (Week 8)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the six-minute walk test</measure>
    <time_frame>end of Period 2 (Week 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the six-minute walk test</measure>
    <time_frame>end of Period 1 (Week 8) compared to end of Period 2 (Week 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures to include assessments of adverse events, vital signs, ECGs, and laboratory assay results</measure>
    <time_frame>during Period 1 (Weeks 1-8) compared to during Period 2 (Weeks 9-16)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Cardiomyopathy, Hypertrophic</condition>
  <condition>Cardiomyopathy, Hypertrophic, Familial</condition>
  <arm_group>
    <arm_group_label>Perhexiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perhexiline</intervention_name>
    <description>Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline</description>
    <arm_group_label>Perhexiline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Hypertrophic cardiomyopathy with symptoms of moderate-to-severe heart failure

          -  Left ventricular hypertrophy with maximum LV wall thickness ≥ 15 mm

          -  Left ventricular ejection fraction ≥ 50%

          -  Able to perform exercise testing but unable to exceed 75% of the predicted
             age-adjusted maximum level

        Key Exclusion Criteria:

          -  CYP2D6 Poor Metabolizer (PM) status

          -  History of a known chronic liver disease

          -  ALT, AST, alkaline phosphatase, or LDH &gt; 1.5 x upper limit of normal

          -  Total Bilirubin &gt; 2.0 x upper limit of normal

          -  Severe LV outflow obstruction

          -  Asymptomatic patients or cardiomyopathy-related criteria as per protocol

          -  QT interval related criteria as per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Midei, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heart Metabolics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heart Metabolics Call Center</last_name>
    <phone>1-800-206-2434</phone>
    <email>info@heartmetabolics.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>August 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertrophic cardiomyopathy</keyword>
  <keyword>hypertrophic</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>familial hypertrophic cardiomyopathy</keyword>
  <keyword>heart failure</keyword>
  <keyword>cardiopulmonary exercise testing</keyword>
  <keyword>6 minute walk test</keyword>
  <keyword>perhexiline</keyword>
  <keyword>carnitine palmitoyltransferase</keyword>
  <keyword>carbohydrate utilization</keyword>
  <keyword>coronary ischemia</keyword>
  <keyword>angina</keyword>
  <keyword>mixed ion channel effects</keyword>
  <keyword>late sodium current inhibitor</keyword>
  <keyword>calcium channel inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic, Familial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Perhexiline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
